Results 81 to 90 of about 64,427 (282)

Imatinib and hypophosphatemia: Case report and review of literature

Journal of Oncological Sciences, 2017
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated.
Erdem Şen, İrem Öner, Özlem Ata
doaj   +1 more source

Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS [PDF]

, 2011
The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C&
Elliott, M., Holyoake, T.L., Iqbal, Z., Jorgensen, H.G., Watson, D.G.   +4 more
core   +1 more source

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Alzuherri, Aytekin, Barjesteh van Waalwijk van Doorn-Khosrovani, Bartholomew, Ben-Neriah, Bianchini, Carapeti, Carlesso, Daghistani, De Weer, Elrick, Fabbro, Fears, Gerhardt, Goyama, Hamilton, Henzan, Hoyt, Huang, Håkansson, Irvine, Jørgensen, Khanna-Gupta, Kilbey, Konopka, Kurzrock, Kustikova, Lin, Livak, Lugthart, Lugthart, Melo, Mitani, Morishita, Morishita, Morishita, Morishita, Nakamura, Nunoda, O'Hare, Ogawa, Paquette, Pendergast, Russell, Sellers, Skorski, Smith, Stevens-Kroef, Suzukawa, Valent, Wetzler, Wieser, Wimmer, Yuasa   +53 more
core   +1 more source

Promotion of Autophagy and Apoptosis in Colorectal Cancer Exposed to Imatinib and Thymoquinone

Journal of Biochemical and Molecular Toxicology, Volume 39, Issue 4, April 2025.
The combination of IM and TQ induced autophagy in HCT116 cell line which in turn enhanced apoptosis. The combination inhibited colonies formation as well as the increments of various apoptotic markers. AMPK, when senses the rising autophagy, it will always activate apoptosis in a stress‐defense response.
Dalia El‐Khouly, Nadia A. Thabet, Mohamed Sayed‐Ahmed, Mervat M. Omran   +3 more
wiley   +1 more source

XML Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia

Iranian Journal of Blood and Cancer, 2016
Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML).
Abolghasem Allahyari, Foroogh Salehi, Mostafa Kaboli, Masoud Sadeghi   +3 more
doaj  

STAT3 Signaling Pathway in Health and Disease

MedComm, Volume 6, Issue 4, April 2025.
An image depicting the role of STAT3 in various human diseases ABSTRACT Signal transducer and activator of transcription 3 (STAT3) is a critical transcription factor involved in multiple physiological and pathological processes. While STAT3 plays an essential role in homeostasis, its persistent activation has been implicated in the pathogenesis of ...
Md Abdus Samad, Iftikhar Ahmad, Aakifah Hasan, Mohammad Hassan Alhashmi, Arusha Ayub, Fahad A. Al‐Abbasi, Ajoy Kumer, Shams Tabrez   +7 more
wiley   +1 more source

Monitoring Twenty-Six Chronic Myeloid Leukemia Patients by BCR-ABL mRNA Level in Bone Marrow: A Single Hospital Experience [PDF]

, 2011
Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by
Akagi, Tomoaki, Kaimori, Mitsuomi, Kubo, Kohmei, Mariya, Yasushi, Ogura, Kazuto, Oshikiri, Toshiyuki, Sakamoto, Yuichi, Sasaki, Sumiko, Segawa, Megumi, Teshiromori, Ryuichi   +9 more
core   +1 more source

The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair

International Wound Journal, Volume 22, Issue 4, April 2025.
ABSTRACT Tyrosine kinase inhibitors (TKIs) can treat various cancers, primarily through their antiangiogenic effects. However, as angiogenesis is crucial for successful wound healing, TKIs may adversely impact wound repair. This review analysed all 63 FDA‐approved TKIs and identified evidence for wound healing and repair implications in 24 agents.
William J. Nahm, Vincent Falanga
wiley   +1 more source

The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

Advances in Hematology, 2010
Imatinib mesylate, showed encouraging activity in chronic myelogenous leukemia. However, there are few data regarding his efficacy and response monitoring in Sub-Saharan African patients. Our objective was to assess response to imatinib mesylate (Glivec)
K. G. Koffi, D. C. Nanho, E. N'dathz, P. Kouehion, R. Dissieka, A. Attia, K. Mozard, A. Tolo, K. Boidy, N. Meité, R. Ayemou, M. Sekongo, N. Tea, I. Sanogo   +13 more
doaj   +1 more source

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Journal of Clinical Oncology, 2008
PURPOSE The outcome of patients diagnosed with advanced gastrointestinal stromal tumor (GIST) and treated long-term with imatinib mesylate is unknown. A previous report of a randomized phase II trial of imatinib mesylate in patients with incurable GIST ...
C. Blanke, G. Demetri, M. von Mehren, M. Heinrich, B. Eisenberg, J. Fletcher, C. Corless, C. Fletcher, P. Roberts, Daniela Heinz, Elisabeth Wehre, Z. Nikolova, H. Joensuu   +12 more
semanticscholar   +1 more source